19 completed, 4 terminated, 3 active not recruiting, 2 unknown. 30 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 19, Terminated 4, Active not recruiting 3, Unknown 2, Withdrawn 2 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study - Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 18 | 2018-02-26 | 2024-12-10 |
| HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis - Recurrent Glioblastoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2017-09-14 | 2022-05-09 |
| Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study - Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 3 | 2017-02-23 | 2025-03-14 |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study - Metastatic Melanoma, Recurrent Cutaneous Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2016-12-16 | 2026-08-11 |
| Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors Carvedilol, Laboratory Biomarker Analysis, Pharmacogenomic Study - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Completed | Children's Oncology Group | 196 | 2016-04-04 | 2025-04-23 |
| LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients Pharmacogenomic Testing - Malignant Tumor of Ill-defined Site | Phase 2 | Terminated | Wake Forest University Health Sciences | 75 | 2015-09-01 | 2022-11-03 |
| Pembrolizumab in Treating Patients With Malignant Mesothelioma Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study - Biphasic Mesothelioma, Epithelioid Mesothelioma | Phase 2 | Completed | University of Chicago | 65 | 2015-03-31 | 2026-05-08 |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis - Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2013-01-01 | 2014-09-09 | |
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 23 | 2011-10-03 | 2023-07-27 |
| Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies - Lung Cancer | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 102 | 2011-07-01 | 2018-07-12 |
| Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies - Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx | Phase 2 | Terminated | Case Comprehensive Cancer Center | 2 | 2011-01-01 | 2020-05-12 |
| Vismodegib in Treating Patients With Advanced Chondrosarcomas Laboratory Biomarker Analysis, Pharmacogenomic Study, Vismodegib - Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 45 | 2010-12-21 | 2026-08-13 |
| Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Tamoxifen Citrate, Placebo, Digital mammography - Breast Cancer | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 84 | 2010-09-01 | 2026-01-05 |
| Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer FOLFIRI regimen, fluorouracil, irinotecan hydrochloride - Colorectal Cancer | Phase 2 | Completed | Cardiff University | 111 | 2010-04-01 | 2014-07-08 |
| Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study - Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2009-11-03 | 2026-09-14 |
| Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye bevacizumab, temozolomide, polymorphism analysis - Intraocular Melanoma | Phase 2 | Unknown | Institut Curie | 35 | 2009-10-01 | 2013-08-26 |
| Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery FOLFIRI regimen, fluorouracil, irinotecan hydrochloride - Colorectal Cancer, Metastatic Cancer | Phase 2 | Withdrawn | Federation Francophone de Cancerologie Digestive | 2009-04-01 | 2022-08-30 | |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer saracatinib, pharmacogenomic studies, pharmacological study - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2008-10-01 | 2019-04-02 |
| Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer abiraterone acetate, laboratory biomarker analysis, pharmacogenomic studies - Breast Cancer | Phase 1 / Phase 2 | Completed | Cancer Research UK | 77 | 2008-10-01 | 2017-01-26 |
| Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen tamoxifen citrate, gene expression analysis, pharmacogenomic studies - Breast Cancer, Menopausal Symptoms | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 501 | 2008-06-18 | 2017-08-01 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Rectal Neoplasms (3) · Adenocarcinoma of Lung (2) · Adenocarcinoma, Bronchiolo-Alveolar (2) · Colonic Neoplasms (2) · Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Melanoma (2) · Neoplasm Metastasis (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Follicular (1) · Adrenal Cortex Neoplasms (1)
National Cancer Institute (NCI) (11) · University of Nebraska (2) · Wake Forest University Health Sciences (2) · Cancer Research UK (1) · Cardiff University (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federation Francophone de Cancerologie Digestive (1) · Institut Cancerologie de l'Ouest (1) · Institut Curie (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (21) · France (5) · United Kingdom (3) · Australia (2) · Canada (2) · Belgium (1) · Egypt (1) · Germany (1) · Greece (1) · Netherlands (1) · New Zealand (1) · Singapore (1) · Slovenia (1)
Andrea E Wahner Hendrickson (1) · Anna Pavlick (1) · Anne Thomas, MD (1) · Antoine Italiano (1) · Charles Rudin (1) · Elizabeth C. Reed, MD (1) · Erick Gamelin, MD (1) · Hedy Kindler (1) · Jai Patel, PharmD (1) · James N. Ingle, MD (1) · Johann Sebastian de Bono, MD (1) · Julian R. Molina, MD, PhD (1) · Lee Ratner (1) · Lisa A. Carey, MD (1) · Marcel Devetten, MD (1)
PMID 20098694, PMID 24100924, PMID 24170610, PMID 27716152, PMID 29954415, PMID 31467059, PMID 33661190, PMID 34414777, PMID 37864646, PMID 38608694
N01CM62201 (2), P30CA014599 (2), P30CA015083 (2), P30CA036727 (2), UM1CA186686 (2), UM1CA186704 (2), N01CM00070 (1), N01CM17103 (1), N01CM62202 (1), N01CM62205 (1), N01CM62209 (1), P30CA016086 (1), P50CA136393 (1), R01CA140245 (1), R01CA196854 (1)